$5.15
3.01% yesterday
Nasdaq, Oct 17, 10:00 pm CET
ISIN
US45790W1080
Symbol
INZY
Sector
Industry

Inozyme Pharma Inc Stock price

$5.15
-0.68 11.66% 1M
+0.50 10.75% 6M
+0.89 20.89% YTD
+1.82 54.65% 1Y
-4.17 44.74% 3Y
-12.39 70.64% 5Y
-12.39 70.64% 10Y
Nasdaq, Closing price Thu, Oct 17 2024
-0.16 3.01%
ISIN
US45790W1080
Symbol
INZY
Sector
Industry

Key metrics

Market capitalization $323.08m
Enterprise Value $225.27m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.39
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-92.89m
Free Cash Flow (TTM) Free Cash Flow $-85.69m
Cash position $144.52m
EPS (TTM) EPS $-1.46
P/E forward negative
Short interest 5.88%
Show more

Is Inozyme Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,907 stocks worldwide.

Inozyme Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Inozyme Pharma Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Inozyme Pharma Inc forecast:

Buy
100%

Financial data from Inozyme Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 1.01 1.01
20% 20%
-
-1.01 -1.01
20% 20%
-
- Selling and Administrative Expenses 19 19
2% 2%
-
- Research and Development Expense 71 71
47% 47%
-
-92 -92
31% 31%
-
- Depreciation and Amortization 1.01 1.01
20% 20%
-
EBIT (Operating Income) EBIT -93 -93
30% 30%
-
Net Profit -89 -89
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Inozyme Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inozyme Pharma Inc Stock News

Neutral
GlobeNewsWire
about 14 hours ago
BOSTON, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that interim data from the Company's ongoing Phase 1 SEAPORT 1 of INZ-701 in patients with end-stage kidney disease (ESKD) rec...
Neutral
GlobeNewsWire
11 days ago
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced the appointment of Erik Harris to its Board of Directors, effective October 3, 2024. Mr. Harris, who currently serves as Chief...
Neutral
GlobeNewsWire
about 2 months ago
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, today announced that Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer of Inozyme, will participate in a fireside chat at ...
More Inozyme Pharma Inc News

Company Profile

Inozyme Pharma engages in the research and development of pharmaceutical products. It specializes in developing new medicines for the treatment of abnormal mineralization and ABCC6 deficiency. The company was founded by Axel Bolte, Joseph P. Schlessinger and Demetrios T. Braddock in September 2015 and is headquartered in Boston, MA.

Head office United States
CEO Doug Treco
Employees 59
Founded 2015
Website www.inozyme.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today